Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial
A preventive vaccine for HIV is a crucial public health need; adeno-associated virus (AAV)-mediated antibody gene delivery could be an alternative to immunisation to induce sustained expression of neutralising antibodies to prevent HIV. We assessed safety and tolerability of rAAV1-PG9DP, a recombina...
Saved in:
Published in | The lancet HIV Vol. 6; no. 4; p. e230 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
01.04.2019
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | A preventive vaccine for HIV is a crucial public health need; adeno-associated virus (AAV)-mediated antibody gene delivery could be an alternative to immunisation to induce sustained expression of neutralising antibodies to prevent HIV. We assessed safety and tolerability of rAAV1-PG9DP, a recombinant AAV1 vector encoding the gene for PG9, a broadly neutralising antibody against HIV.
This first-in-human, proof-of-concept, double-blind, phase 1, randomised, placebo-controlled, dose-escalation trial was done at one clinical research centre in the UK. Healthy men aged 18-45 years without HIV infection were randomly assigned to receive intramuscular injection with rAAV1-PG9DP or placebo in the deltoid or quadriceps in one of four dose-escalating cohorts (group A, 4 × 10
vector genomes; group B, 4 × 10
vector genomes; group C, 8 × 10
vector genomes; and group D, 1·2 × 10
vector genomes). Volunteers were followed up for 48 weeks. The primary objective was to assess safety and tolerability. A secondary objective was to assess PG9 expression in serum and related HIV neutralisation activity. All volunteers were included in primary and safety analyses. The trial is complete and is registered with ClinicalTrials.gov, number NCT01937455.
Between Jan 30, 2014, and Feb 28, 2017, 111 volunteers were screened for eligibility. 21 volunteers were eligible and provided consent, and all 21 completed 48 weeks of follow-up. Reactogenicity was generally mild or moderate and resolved without intervention. No probably or definitely related adverse events or serious adverse events were recorded. We detected PG9 by HIV neutralisation in the serum of four volunteers, and by RT-PCR in muscle biopsy samples from four volunteers. We did not detect PG9 by ELISA in serum. PG9 anti-drug antibody was present in ten volunteers in the higher dose groups. Both anti-AAV1 antibodies and AAV1-specific T-cell responses were detected.
Future studies should explore higher doses of AAV, alternative AAV serotypes and gene expression cassettes, or other broadly neutralising HIV antibodies.
International AIDS Vaccine Initiative, United States Agency for International Development, Bill & Melinda Gates Foundation, US National Institutes of Health. |
---|---|
AbstractList | A preventive vaccine for HIV is a crucial public health need; adeno-associated virus (AAV)-mediated antibody gene delivery could be an alternative to immunisation to induce sustained expression of neutralising antibodies to prevent HIV. We assessed safety and tolerability of rAAV1-PG9DP, a recombinant AAV1 vector encoding the gene for PG9, a broadly neutralising antibody against HIV.
This first-in-human, proof-of-concept, double-blind, phase 1, randomised, placebo-controlled, dose-escalation trial was done at one clinical research centre in the UK. Healthy men aged 18-45 years without HIV infection were randomly assigned to receive intramuscular injection with rAAV1-PG9DP or placebo in the deltoid or quadriceps in one of four dose-escalating cohorts (group A, 4 × 10
vector genomes; group B, 4 × 10
vector genomes; group C, 8 × 10
vector genomes; and group D, 1·2 × 10
vector genomes). Volunteers were followed up for 48 weeks. The primary objective was to assess safety and tolerability. A secondary objective was to assess PG9 expression in serum and related HIV neutralisation activity. All volunteers were included in primary and safety analyses. The trial is complete and is registered with ClinicalTrials.gov, number NCT01937455.
Between Jan 30, 2014, and Feb 28, 2017, 111 volunteers were screened for eligibility. 21 volunteers were eligible and provided consent, and all 21 completed 48 weeks of follow-up. Reactogenicity was generally mild or moderate and resolved without intervention. No probably or definitely related adverse events or serious adverse events were recorded. We detected PG9 by HIV neutralisation in the serum of four volunteers, and by RT-PCR in muscle biopsy samples from four volunteers. We did not detect PG9 by ELISA in serum. PG9 anti-drug antibody was present in ten volunteers in the higher dose groups. Both anti-AAV1 antibodies and AAV1-specific T-cell responses were detected.
Future studies should explore higher doses of AAV, alternative AAV serotypes and gene expression cassettes, or other broadly neutralising HIV antibodies.
International AIDS Vaccine Initiative, United States Agency for International Development, Bill & Melinda Gates Foundation, US National Institutes of Health. |
Author | LaBranche, Celia Dally, Len Priddy, Frances H Hassanin, Hana Cox, Josephine H Wright, J Fraser Hare, Jonathan Montefiori, David Johnson, Philip Lewis, David J M Sayeed, Eddy Streatfield, Claire Gelderblom, Huub C Gilmour, Jill Schnepp, Bruce C Ackland, Jim Bendel, Daryl |
Author_xml | – sequence: 1 givenname: Frances H surname: Priddy fullname: Priddy, Frances H email: fpriddy@iavi.org organization: International AIDS Vaccine Initiative, New York, NY, USA. Electronic address: fpriddy@iavi.org – sequence: 2 givenname: David J M surname: Lewis fullname: Lewis, David J M organization: NIHR Imperial Clinical Research Facility, Imperial College, London UK – sequence: 3 givenname: Huub C surname: Gelderblom fullname: Gelderblom, Huub C organization: International AIDS Vaccine Initiative, New York, NY, USA – sequence: 4 givenname: Hana surname: Hassanin fullname: Hassanin, Hana organization: Surrey Clinical Research Centre, University of Surrey, Guildford, UK – sequence: 5 givenname: Claire surname: Streatfield fullname: Streatfield, Claire organization: International AIDS Vaccine Initiative, London, UK – sequence: 6 givenname: Celia surname: LaBranche fullname: LaBranche, Celia organization: Department of Surgery, Duke University Medical Center, Durham, NC, USA – sequence: 7 givenname: Jonathan surname: Hare fullname: Hare, Jonathan organization: International AIDS Vaccine Initiative, London, UK – sequence: 8 givenname: Josephine H surname: Cox fullname: Cox, Josephine H organization: International AIDS Vaccine Initiative, New York, NY, USA – sequence: 9 givenname: Len surname: Dally fullname: Dally, Len organization: The Emmes Company, LLC, Rockville, MD, USA – sequence: 10 givenname: Daryl surname: Bendel fullname: Bendel, Daryl organization: Surrey Clinical Research Centre, University of Surrey, Guildford, UK – sequence: 11 givenname: David surname: Montefiori fullname: Montefiori, David organization: Department of Surgery, Duke University Medical Center, Durham, NC, USA – sequence: 12 givenname: Eddy surname: Sayeed fullname: Sayeed, Eddy organization: International AIDS Vaccine Initiative, New York, NY, USA – sequence: 13 givenname: Jim surname: Ackland fullname: Ackland, Jim organization: Global Biosolutions, Melbourne, Australia – sequence: 14 givenname: Jill surname: Gilmour fullname: Gilmour, Jill organization: International AIDS Vaccine Initiative, London, UK – sequence: 15 givenname: Bruce C surname: Schnepp fullname: Schnepp, Bruce C organization: Children's Hospital of Philadelphia – sequence: 16 givenname: J Fraser surname: Wright fullname: Wright, J Fraser organization: Children's Hospital of Philadelphia – sequence: 17 givenname: Philip surname: Johnson fullname: Johnson, Philip organization: Children's Hospital of Philadelphia |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30885692$$D View this record in MEDLINE/PubMed |
BookMark | eNo9kD1PwzAYhC0EoqX0J4A8whCwnThx2KoKaKVKDHys1RvbUYwSO7Kdqvn3BPEx3d0znHR3gU6tsxqhK0ruKKH5_StLOUtSQsUNLW9TQkiaFCdo_o9naBnC58QpzwTP2DmapUQInpdsjsaV0tYlEIKTBqJW-GD8EPBBy-j8FE3XDdb13vXN2MLRBBwd7r0-aBvxZvuBjcWNhjY2IwY1tDE8YMB9A0Fjij1Y5ToTpiLpbPSubScbvYH2Ep3V0Aa9_NUFen96fFtvkt3L83a92iWS0zImJad5pnLKRM61lpQVAgrQnBNZkCwvQFKuhPqeVkNZ1QwoSC6yOiUVZ1XJFuj6p7cfqk6rfe9NB37c_33AvgBxPGGi |
CitedBy_id | crossref_primary_10_3389_fmed_2021_809118 crossref_primary_10_1016_j_omtm_2019_06_002 crossref_primary_10_3389_fimmu_2021_673699 crossref_primary_10_3389_fimmu_2020_00449 crossref_primary_10_4049_jimmunol_2100340 crossref_primary_10_1084_jem_20220110 crossref_primary_10_3389_frph_2023_1337479 crossref_primary_10_3390_vaccines8040758 crossref_primary_10_1038_s41392_021_00631_2 crossref_primary_10_1093_infdis_jiaa377 crossref_primary_10_1016_j_cbpa_2023_102281 crossref_primary_10_1038_s41591_022_01762_x crossref_primary_10_1016_j_omtm_2023_02_004 crossref_primary_10_1128_jvi_00211_23 crossref_primary_10_3390_antib12030046 crossref_primary_10_1016_j_omtm_2020_04_019 crossref_primary_10_1016_j_jim_2024_113657 crossref_primary_10_1038_s41531_023_00542_9 crossref_primary_10_1111_hae_14780 crossref_primary_10_1016_j_smim_2020_101412 crossref_primary_10_3390_v16060911 crossref_primary_10_1016_j_jconrel_2021_09_006 crossref_primary_10_1016_j_jim_2020_112764 crossref_primary_10_3389_fimmu_2021_734304 crossref_primary_10_1371_journal_ppat_1011780 crossref_primary_10_1136_thoraxjnl_2021_217650 crossref_primary_10_3389_fneur_2022_870799 crossref_primary_10_1089_hum_2023_123 crossref_primary_10_3390_pharmaceutics13111882 crossref_primary_10_1038_s41586_019_1841_8 crossref_primary_10_1080_22221751_2020_1787108 crossref_primary_10_3390_vaccines9020108 crossref_primary_10_1016_j_antiviral_2023_105788 crossref_primary_10_1097_COH_0000000000000803 crossref_primary_10_3390_biomedicines11082223 crossref_primary_10_2174_1570162X18666200210121339 crossref_primary_10_1097_COH_0000000000000600 crossref_primary_10_1016_j_ymthe_2024_05_036 crossref_primary_10_1146_annurev_med_110118_045506 crossref_primary_10_1038_s41591_021_01590_5 crossref_primary_10_3389_fimmu_2021_787603 crossref_primary_10_3390_biomedicines10123162 crossref_primary_10_1089_hum_2023_056 crossref_primary_10_1016_j_celrep_2021_110061 crossref_primary_10_1038_s41587_022_01328_9 crossref_primary_10_1016_j_coviro_2022_101211 crossref_primary_10_3390_vaccines7030119 crossref_primary_10_3390_microorganisms9020228 crossref_primary_10_1016_j_omtm_2019_11_010 crossref_primary_10_1080_22221751_2020_1713707 crossref_primary_10_1360_TB_2022_1097 crossref_primary_10_1172_JCI132779 crossref_primary_10_1016_j_smim_2021_101475 crossref_primary_10_1007_s40259_023_00585_7 crossref_primary_10_1007_s40259_020_00412_3 crossref_primary_10_1080_14760584_2020_1718497 crossref_primary_10_3389_fimmu_2021_712122 crossref_primary_10_1172_jci_insight_143958 crossref_primary_10_1080_14760584_2023_2193266 crossref_primary_10_1128_cmr_00152_22 crossref_primary_10_1038_s41467_020_19649_1 crossref_primary_10_1016_j_scib_2023_11_015 crossref_primary_10_1038_s41434_022_00361_2 crossref_primary_10_3389_fimmu_2023_1105617 crossref_primary_10_3390_microorganisms9091956 crossref_primary_10_1371_journal_pntd_0007860 crossref_primary_10_3390_tropicalmed5040169 crossref_primary_10_1042_BCJ20200610 crossref_primary_10_1155_2024_2147912 crossref_primary_10_3390_vaccines9091026 crossref_primary_10_1016_j_jve_2023_100316 crossref_primary_10_3389_fcimb_2020_00176 crossref_primary_10_1007_s00705_022_05432_8 crossref_primary_10_1016_j_antiviral_2024_105867 crossref_primary_10_1016_j_omtm_2023_01_006 crossref_primary_10_4103_1673_5374_353482 crossref_primary_10_1016_j_ymthe_2021_09_019 crossref_primary_10_1016_S2352_3018_19_30041_4 crossref_primary_10_1089_hum_2021_105 crossref_primary_10_1097_COH_0000000000000666 crossref_primary_10_3390_ph14060554 crossref_primary_10_1088_1748_605X_ac4e64 |
ContentType | Journal Article |
Copyright | Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. |
Copyright_xml | – notice: Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1016/S2352-3018(19)30003-7 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2352-3018 |
ExternalDocumentID | 30885692 |
Genre | Clinical Trial, Phase I Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GeographicLocations | United Kingdom |
GeographicLocations_xml | – name: United Kingdom |
GrantInformation | International AIDS Vaccine Initiative, United States Agency for International Development, Bill & Melinda Gates Foundation, US National Institutes of Health. |
GrantInformation_xml | – fundername: NIAID NIH HHS grantid: R01 AI106509 |
GroupedDBID | -RU .1- .FO 0R~ 1P~ 4.4 457 53G AAEDT AAEDW AALRI AAMRU AAQFI AAXUO ABJNI ACGFS ADBBV AENEX AFRHN AFTJW AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ CGR CUY CVF EBS ECM EIF EJD FDB HZ~ M41 NPM O9- OD- OO. ROL Z5R |
ID | FETCH-LOGICAL-c519t-95164d612865eec1278a7ae550c70467ac15d8d5485fa9bf2a1ac584f30b52b92 |
IngestDate | Sat Nov 02 12:29:46 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
License | Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c519t-95164d612865eec1278a7ae550c70467ac15d8d5485fa9bf2a1ac584f30b52b92 |
OpenAccessLink | http://www.thelancet.com/article/S2352301819300037/pdf |
PMID | 30885692 |
ParticipantIDs | pubmed_primary_30885692 |
PublicationCentury | 2000 |
PublicationDate | 2019-04-01 |
PublicationDateYYYYMMDD | 2019-04-01 |
PublicationDate_xml | – month: 04 year: 2019 text: 2019-04-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | The lancet HIV |
PublicationTitleAlternate | Lancet HIV |
PublicationYear | 2019 |
References | 30885694 - Lancet HIV. 2019 Apr;6(4):e207-e208. doi: 10.1016/S2352-3018(19)30041-4 30954489 - Lancet HIV. 2019 Dec;6(12):e815. doi: 10.1016/S2352-3018(19)30107-9 |
References_xml | |
SSID | ssj0001548542 |
Score | 2.489389 |
Snippet | A preventive vaccine for HIV is a crucial public health need; adeno-associated virus (AAV)-mediated antibody gene delivery could be an alternative to... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | e230 |
SubjectTerms | Adolescent Adult Antibodies, Neutralizing - blood Antibodies, Neutralizing - genetics Dependovirus - genetics Double-Blind Method Follow-Up Studies Genetic Therapy - adverse effects Genetic Therapy - methods Genetic Vectors Healthy Volunteers HIV Antibodies - blood HIV Antibodies - genetics HIV Infections - prevention & control Humans Injections, Intramuscular Male Middle Aged Neutralization Tests Placebos - administration & dosage Recombinant Proteins - blood Recombinant Proteins - genetics United Kingdom Young Adult |
Title | Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial |
URI | https://www.ncbi.nlm.nih.gov/pubmed/30885692 |
Volume | 6 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLU6EGgviO9v5AeQQFGgzrd5mxAQTbAXNmlvk-3YIlJJqrXdVn4RP5NjO2miDhDwEqWxaqX3ntwc3_rcS8hzMVU5x0hojBA2dSPDQvMi1IpFQjItp7FVI38-yMqjZP84PZ5Mfox2La2W8rX6_ktdyf94FdfgV6uS_QfPbibFBZzDvzjCwzj-lY_3EDTaUHQWBnU8q09Xi-DMZeLxsbbijxYxEraciYvaVXOY-6JNQYmFX910Qsi1L8Sx8Nrn-Ve82wIW4D1WtQCCrvot7TOcukYfY1JroTZzWmo76SbYntaVj-CueYdeDDqIT_rclzZwO-qD_SEl-1HbruFy1jqYlquVHNK4JX6oaHzNg1L4rt99woLx0T4X7QJbBNIXIrAU4yicjcCWjCKqjvz_NpdCvc86fNlMZuta8RdgL3aZF-bj78B2828OAzGCapr57nt_Ht2qwt0P7ZCdvLAtQg66rJBXoydFmkSDQOzNcFsvGX_V3dIuud5Ps7WIcWTm8Ca50a1C6J6H1C0y0c1tcs33JV3fIettYFEHLNoDi14CFl22tAMWBQZo3dAOWNQD6y0V1MGKMjrAig6wog5Wd8nRh_eH78qw69ERKnD_ZQiCniUVaHKRpdo-4HkhcqGx7lX5FC9hoVhaFZU1kBFcmkgwoUB6TTyVaSR5dI9cadpGPyA0V1WcGCtXSmXC8kzGCdis4dqorDIxf0jue5udzH0hlpPemo9-O_KY7A4QfEKuGjz5-ilo5FI-cz78CTe2cqI |
link.rule.ids | 780 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Adeno-associated+virus+vectored+immunoprophylaxis+to+prevent+HIV+in+healthy+adults%3A+a+phase+1+randomised+controlled+trial&rft.jtitle=The+lancet+HIV&rft.au=Priddy%2C+Frances+H&rft.au=Lewis%2C+David+J+M&rft.au=Gelderblom%2C+Huub+C&rft.au=Hassanin%2C+Hana&rft.date=2019-04-01&rft.eissn=2352-3018&rft.volume=6&rft.issue=4&rft.spage=e230&rft_id=info:doi/10.1016%2FS2352-3018%2819%2930003-7&rft_id=info%3Apmid%2F30885692&rft_id=info%3Apmid%2F30885692&rft.externalDocID=30885692 |